FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

A f = =  -	-	20540
<i>N</i> ashington,	D.C.	20549

Washington, D.C. 20045	
CTATEMENT OF CHANCES IN DENETICE	L OWNEDCHID
STATEMENT OF CHANGES IN BENEFICIA	AL OWNERSHIP

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average burden									
hours per response:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  Donegan Michael C					2. Issuer Name <b>and</b> Ticker or Trading Symbol TherapeuticsMD, Inc. [TXMD]						5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director 10% Owner					
										X	Officer (gi	ve title		Other (sp		
(Last) (First) (Middle) 951 YAMATO ROAD SUITE 220					3. Date of Earliest Transaction (Month/Day/Year) 11/30/2021						CAO and VP of Finance					
(Street)	ATON I	FL	33431	4. If A	4. If Amendment, Date of Original Filed (Month/Day/Year)						Individual or Joint/Group Filing (Check Applicable Line)  X Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City)	(	State)	(Zip)													
			Table I - No	n-Derivative	Securities Ac	quire	d, Dis	sposed o	of, or Ben	eficially O	vned					
Date			2. Transaction Date (Month/Day/Year)	Execution Date,		3. Transaction Code (Instr. 8)  4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and Code (Instr. 8)				5. Amount of Securities Beneficially Owned Following Reported		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)		
						Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)				iiisu. 4)	
Common	Stock			11/30/2021		М		115,00	0 A	(1)	(1) 129,158 D			D		
Common	Stock			11/30/2021		S <sup>(2)</sup>		29,790	) D	\$0.5353(3)	0.5353 <sup>(3)</sup> 99,368 D					
			Table II -		Securities Acq						ned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Yea	Code (Instr.	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)  7. Title and Amore Securities Under Derivative Secur 3 and 4)		Inderlying	8. Price of Derivative Security (Instr. 5)  8. Price of derivative Security Security Owned Followi		ve es ially	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)			

## Explanation of Responses:

\$0.00

1. On November 30, 2021, the reporting person received 115,000 shares of issuer common stock in settlement of restricted stock units (RSUs), which vested on November 24, 2021.

115,000(1)(4)

(A) (D)

Code

- 2. The reported securities represent shares of issuer common stock sold upon settlement to satisfy tax obligations.
- 3. The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions with prices ranging from \$0.4819 to \$0.5503 for an average weighted sale price of \$0.5353. The reporting person undertakes to provide the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

Date Exercisable

(5)

Expiration Date

(5)

Title

Stock

- 4. Each RSU represents a contingent right to receive one share of issuer common stock upon settlement.
- 5. The RSUs vest in two equal installments on November 24, 2021 and November 24, 2022.

11/30/2021

## Remarks:

Restricted

Units

/s/ Michael C. Donegan

12/02/2021

(Instr. 4)

Following Reported Transaction(s)

115,000

D

\*\* Signature of Reporting Person

Amount or

Number of Shares

115,000(1)(4)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.